MedPath

Paclitaxel With or Without Carboplatin in Treating Women With Metastatic Breast Cancer

Phase 3
Conditions
Breast Cancer
Registration Number
NCT00025688
Lead Sponsor
Theradex
Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if paclitaxel is more effective with or without carboplatin in treating stage IV breast cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of paclitaxel with or without carboplatin in treating women who have stage IV breast cancer.

Detailed Description

OBJECTIVES:

* Compare the objective response rate in women treated with paclitaxel with or without carboplatin as first-line chemotherapy for metastatic breast cancer.

* Compare the overall survival, time to disease progression, and duration of response in these patients treated with these regimens.

* Compare the safety of these regimens in this patient population.

* Compare the quality of life of these patients treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to prior adjuvant chemotherapy (yes vs no) and ECOG performance status (0-1 vs 2). Patients are randomized to one of two treatment arms.

* Arm I: Patients receive paclitaxel IV over 1 hour weekly for 3 weeks.

* Arm II:Patients receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes weekly for 3 weeks.

Treatment in both arms continues every 4 weeks in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline, before each course during study, and then after completion of study.

Patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 220 patients will be accrued for this study.

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (25)

Highlands Oncology Group

🇺🇸

Springdale, Arkansas, United States

Monterey Bay Oncology

🇺🇸

Monterey, California, United States

Wilshire Oncology Medical Group, Inc.

🇺🇸

Pomona, California, United States

University of California Davis Cancer Center

🇺🇸

Sacramento, California, United States

New Britain General Hospital

🇺🇸

New Britain, Connecticut, United States

Center for Hematology and Oncology

🇺🇸

Boca Raton, Florida, United States

Cancer Research Network, Inc.

🇺🇸

Hollywood, Florida, United States

Mayo Clinic

🇺🇸

Jacksonville, Florida, United States

MacNeal Cancer Center

🇺🇸

Berwyn, Illinois, United States

Oncology Specialists, SC

🇺🇸

Park Ridge, Illinois, United States

Scroll for more (15 remaining)
Highlands Oncology Group
🇺🇸Springdale, Arkansas, United States
© Copyright 2025. All Rights Reserved by MedPath